Alternatively, our finding that NEP negatively regulates ERK phosphorylation through the degradation of ET-1 in breast cancer cells (Figure 3) suggests that targeting either the MAPK pathway or the ET axis could mimic reactivation of NEP in breast cancer therapy, particularly in ER-negative breast cancers. Here, MME is linked to breast carcinoma.